Biomarker testing plays an established role in advanced non-small cell lung cancer (NSCLC), but access, testing pathways and turnaround times continue to vary across regions. These FAQs address common questions about lung cancer biomarker testing, regional implementation, and the practical considerations for biomarker-defined clinical trials.
1. Is biomarker testing standard of care in advanced NSCLC?
Biomarker testing is expected in advanced non-small cell lung cancer (NSCLC), and its role in guiding treatment selection is well established. However, the available evidence does not support describing biomarker testing as a uniformly implemented global standard. In practice, the testing pathway depends on whether the right assay is performed on an adequate specimen and whether the result is available in time to inform first-line treatment.
2. Why does turnaround time matter in lung cancer biomarker testing?
Turnaround time is critical because a biomarker result that arrives after treatment has started may no longer influence the first-line treatment decision. In the 2024 IASLC global survey, over 40% of respondents reported that treatment sometimes or often began before biomarker results were available. For biomarker-driven clinical trials, the same delay can mean that an otherwise eligible patient starts treatment before the study has an opportunity to identify them.
3. What are the main barriers to biomarker and molecular testing in lung cancer?
The main barriers to biomarker and molecular testing in lung cancer include turnaround time, cost, sample quality, access, reimbursement and differences in testing workflows. The dominant barrier varies by region. For example, affordability remains an important constraint in China, access to advanced testing varies across European countries, and delayed results continue to affect testing pathways in parts of Latin America. Assay availability alone therefore does not indicate whether testing can be delivered consistently in routine care.
4. How does biomarker testing in clinical trials affect feasibility?
Biomarker testing can directly affect patient identification, pre-screening yield, screen failure and time to consent. National testing rates alone are not enough to assess feasibility. Sponsors need to understand the full pathway from test initiation to an actionable result, including assay coverage, specimen requirements, testing location and turnaround time. These factors can determine whether biomarker-defined clinical trials are able to identify eligible patients within the study screening window.
5. What should sponsors check before choosing countries for a biomarker-defined NSCLC trial?
Sponsors should assess five linked areas of biomarker readiness: how testing is initiated, whether the routine panel covers the required biomarker and alteration type, which specimen types are accepted, where and how quickly testing is performed, and who pays for it. Reviewing these factors at country and site level provides a more realistic picture of NSCLC biomarker testing readiness than laboratory capability alone.





